Astria Therapeutics, Inc. (ATXS)
Jan 26, 2026 - ATXS was delisted (reason: acquired by BCRX)
12.58
0.00 (0.00%)
Inactive · Last trade price
on Jan 22, 2026
Astria Therapeutics Employees
Astria Therapeutics had 78 employees as of December 31, 2024. The number of employees increased by 19 or 32.20% compared to the previous year.
Employees
78
Change (1Y)
19
Growth (1Y)
32.20%
Revenue / Employee
$9,051
Profits / Employee
-$1,590,128
Market Cap
718.13M
Employees Chart
ATXS News
- 5 weeks ago - Astria Stockholders Vote to Approve Acquisition by BioCryst - Business Wire
- 3 months ago - Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold - Seeking Alpha
- 3 months ago - Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - Business Wire
- 4 months ago - Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart - Business Wire
- 4 months ago - Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
- 4 months ago - Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS - Business Wire
- 4 months ago - BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
- 4 months ago - BioCryst to buy Astria Therapeutics in $700 million deal - Reuters